{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:48:46Z","timestamp":1790092126364,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Piperacillin-tazobactam (TZP) is a commonly used broad-spectrum antibiotic in clinical practice; however, its haematopoietic toxicity profile has not yet been fully elucidated. This study combines clinical case observations with large-scale pharmacovigilance data to characterize TZP-associated thrombocytopenia and anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We first report a case series of three patients presenting with distinct TZP-associated haematopoietic injuries, including severe thrombocytopenia complicated by mild anemia, as well as mixed haematopoietic toxicity predominantly manifested as anemia, with or without concomitant thrombocytopenia. Subsequently, a disproportionality analysis was performed on the FDA Adverse Event Reporting System (FAERS) database using four quantitative methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The disproportionality analysis confirmed a significant and robust risk signal for TZP-associated thrombocytopenia (ROR = 5.26, 95% CI 4.81\u20135.74), which remained stable in sensitivity analyses adjusting for concomitant medications. Although the signal for anemia was relatively weak across all methods, the clinical cases provided key evidence supporting the occurrence of this adverse reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TZP can induce severe thrombocytopenia. It is recommended to actively monitor complete blood counts, with particular attention to platelet, erythrocyte, and hemoglobin levels, within the first week of treatment initiation. When encountering unexplained cytopenia in clinical practice, TZP should be considered as a potential causative agent; if the drug is highly suspected, immediate discontinuation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1817103","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:05Z","timestamp":1779342185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Thrombocytopenia and anemia associated with piperacillin-tazobactam: integrating clinical case series with FAERS disproportionality analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Lu","sequence":"first","affiliation":[{"name":"Pharmacy Department, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Department, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Liwan Central Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.4065\/78.7.869","article-title":"The hematologic system as a marker of organ dysfunction in sepsis","volume":"78","author":"Aird","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1133351","DOI":"10.3389\/fimmu.2023.1133351","article-title":"Blood count derangements after sepsis and association with post-hospital outcomes","volume":"14","author":"Denstaedt","year":"2023","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/ejhpharm-2017-001243","article-title":"A case of probable piperacillin\/tazobactam-induced bone marrow suppression in a pregnant woman","volume":"26","author":"ElSalem","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"005460","DOI":"10.12890\/2025_005460","article-title":"Piperacillin\/tazobactam induced immune-mediated anaemia and thrombocytopenia","volume":"12","author":"Fritz","year":"2025","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1396994","DOI":"10.3389\/fphar.2024.1396994","article-title":"An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients","volume":"15","author":"Fu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/imj.15243","article-title":"Piperacillin-tazobactam-induced haemolytic anaemia after multiple courses of therapy","volume":"51","author":"Gerhardy","year":"2021","journal-title":"Intern Med. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4021\/jocmr2009.03.1227","article-title":"Piperacillin\/Tazobactam induced myelosuppression","volume":"1","author":"Lee","year":"2009","journal-title":"J. Clin. Med. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/TA.0000000000002147","article-title":"Persistent inflammation and anemia among critically ill septic patients","volume":"86","author":"Loftus","year":"2019","journal-title":"J. Trauma Acute Care Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0032-1328882","article-title":"Antimicrobial drug-induced thrombocytopenia: a review of the literature","volume":"38","author":"Loo","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"B12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000440673","article-title":"Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre","volume":"42","author":"Mayer","year":"2015","journal-title":"Transfus. Med. Hemother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"bcr2016216937","DOI":"10.1136\/bcr-2016-216937","article-title":"Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis","volume":"2016","author":"Meinus","year":"2016","journal-title":"BMJ Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting system (FAERS) database","volume":"25","author":"Morris","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"B15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4103\/0970-9185.98368","article-title":"Piperacillin\/Tazobactem induced epistaxis- A case report","volume":"28","author":"Tomar","year":"2012","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne","year":"2020","journal-title":"J. Clin. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1097\/00003246-199912000-00005","article-title":"Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients","volume":"27","author":"von Ahsen","year":"1999","journal-title":"Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11096-020-01071-8","article-title":"Hematologic adverse effects induced by piperacillin-tazobactam: a systematic review of case reports","volume":"42","author":"Wang","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e45675","DOI":"10.1097\/MD.0000000000045675","article-title":"Piperacillin-tazobactam-induced hemophagocytic lymphohistiocytosis in a patient with community-acquired pneumonia: a case report and literature review on diagnostic challenges of elevated procalcitonin","volume":"104","author":"Xia","year":"2025","journal-title":"Med. Baltim."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2165\/00019053-200119110-00006","article-title":"Piperacillin\/Tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections","volume":"19","author":"Young","year":"2001","journal-title":"Pharmacoeconomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:07Z","timestamp":1779342187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":20,"alternative-id":["10.3389\/fphar.2026.1817103"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1817103","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1817103"}}